ABBV vs. ONC: AbbVie vs. BeOne Medicines Stock Comparison
How do AbbVie (ABBV) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AbbVie (ABBV) and BeOne Medicines (ONC) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
AbbVie (ABBV) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ABBV | ONC |
|---|---|---|
| Name | AbbVie Inc. | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 514.92 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | January 2, 2013 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ABBV | ONC |
|---|---|---|
| Total Return (1Y) | 37.33% | 30.59% |
| Total Return (3Y, Annualized) | 32.74% | 30.15% |
| Total Return (5Y, Annualized) | 24.73% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ABBV | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 25.65% | 35.90% |
| Beta (5Y) | 0.21 | 0.59 |
| Max Drawdown (5Y) | -21.92% | -68.89% |
| Avg. Volume (3M) | 4.76M | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ABBV | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 1.29 | 0.73 |
| Sortino Ratio (1Y) | 2.02 | 1.15 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: BeOne Medicines (ONC) earns 18.40% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ABBV
- --
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both AbbVie (ABBV) at 15.67% and BeOne Medicines (ONC) at 13.86% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.67%
- Max
- 18.05%
- ABBV
- 15.67%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both AbbVie (ABBV) at 39.59% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.59%
- Max
- 83.12%
- ABBV
- 39.59%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ABBV | ONC |
|---|---|---|
| ROE (TTM) | -- | 18.40% |
| ROA (TTM) | 10.74% | 8.42% |
| Net Margin (TTM) | 15.67% | 13.86% |
| Operating Margin (TTM) | 39.59% | 22.15% |
| Gross Margin (TTM) | 73.72% | 89.39% |
Growth
Revenue Growth
Both AbbVie (ABBV) at 8.57% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: AbbVie (ABBV) reports EPS growth of -0.84%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | ABBV | ONC |
|---|---|---|
| Revenue Growth (YoY) | 8.57% | 40.23% |
| Revenue Growth (3Y CAGR) | 1.75% | 55.69% |
| EPS Growth (YoY) | -0.84% | -- |
| EPS Growth (3Y CAGR) | -29.03% | -- |
Financial Strength
Current Ratio (MRQ)
BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ABBV
- 0.87
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: BeOne Medicines (ONC) carries debt-to-equity ratio of 0.35 against its industry range, while AbbVie (ABBV) reports no figure this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- ABBV
- --
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ABBV | ONC |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 3.55 |
| Debt / Equity (MRQ) | -- | 0.35 |
| Net Debt / EBITDA | 2.21 | -2.80 |
Dividends
Dividend Yield (TTM)
BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.40%
- ABBV
- 2.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; BeOne Medicines (ONC) pays no dividend (payout 0.00%).
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.35%
- ABBV
- 117.35%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ABBV | ONC |
|---|---|---|
| Dividend Yield (TTM) | 2.40% | 0.00% |
| Dividend Payout Ratio (TTM) | 117.35% | 0.00% |
Valuation
P/E Ratio (TTM)
Both AbbVie (ABBV) at 50.05 and BeOne Medicines (ONC) at 52.17 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
50.05
- Max
- 85.34
- ABBV
- 50.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both AbbVie (ABBV) at 7.80 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.80
- Max
- 58.18
- Q3
- 25.77
- ABBV
- 7.80
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile BeOne Medicines (ONC) reports 7.98, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-112.34
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- ABBV
- -112.34
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ABBV | ONC |
|---|---|---|
| P/E Ratio (TTM) | 50.05 | 52.17 |
| P/S Ratio (TTM) | 7.80 | 7.04 |
| P/B Ratio (MRQ) | -112.34 | 7.98 |
| Free Cash Flow Yield (TTM) | 3.44% | 2.21% |